Moberg Pharma (Sweden)

Research works: 4
Citations: 66
Top-10% rate: 0.0%
Open access: 48%
International: 57%

Not ranked overall: Moberg Pharma (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Moberg Pharma (Sweden) work in?

In all years, 56% of research at Moberg Pharma (Sweden) is in Health Sciences, 22% in Social Sciences. Its largest fields are Medicine (56%), Social Sciences (22%), Biochemistry, Genetics and Molecular Biology (13%). It does 1.4× the world's share of Health Sciences.

Life Sciences20%Physical Sciences2%Health Sciences56%Social Sciences22%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 5 fields, with their numbers

Health Sciences255.6%
1. Medicine255.6%
Social Sciences122.2%
1. Social Sciences122.2%
Life Sciences120.0%
1. Biochemistry, Genetics and Molecular Biology113.3%
2. Immunology and Microbiology06.7%
Physical Sciences02.2%
1. Environmental Science02.2%

All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

What are the most cited papers from Moberg Pharma (Sweden)?

The most cited paper from Moberg Pharma (Sweden) is "A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*" (Boni Elizabeth Elewski et al., 2020), with 42 citations. Next come "Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24‐week, double‐blind, placebo‐controlled study" (30) and "Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double‐blind, randomised, placebo‐controlled studies" (30).

Most cited papers
#	Paper	Released	Citations
1	A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail* Boni Elizabeth Elewski et al. · British Journal of Dermatology	18 May 2020	42
2	Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24‐week, double‐blind, placebo‐controlled study Lennart Emtestam, Taavi Kaaman, Kjell Rensfeldt · Mycoses	11 Jun 2012	30
3	Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double‐blind, randomised, placebo‐controlled studies Lennart Emtestam, Åke Svensson, Kjell Rensfeldt · Mycoses	4 Oct 2011	30
4	Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study Aditya Gupta, Maria S. Surprenant, Steven E. Kempers et al. · Journal of the American Academy of Dermatology	22 Jun 2020	29
5	The Voting System in the Council of the European Union. The Balance Between Large and Small Countries1 Axel Moberg · Scandinavian Political Studies	Nov 1998	16

All 12 most cited papers, with filters and sorting

Which research topics does Moberg Pharma (Sweden) publish most on?

By volume in 2022-now: Clostridium difficile and Clostridium perfringens research, Nail Diseases and Treatments, Antibiotic Use and Resistance and Nosocomial Infections in ICU.

Infectious DiseasesEpidemiologyApplied Microbiology and BiotechnologyCritical Care and Intensive Care Medicine1 others

Area is fractional works; colour is the subfield each topic belongs to.

1 Clostridium difficile and Clostridium perfringens research Infectious Diseases 0 works
2 Nail Diseases and Treatments Epidemiology 0 works
3 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 0 works
4 Nosocomial Infections in ICU Critical Care and Intensive Care Medicine 0 works
5 Plant Pathogens and Fungal Diseases Cell Biology 0 works
6 Fungal Infections and Studies Epidemiology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

48%52%

openly available48.3%not open51.7%

World: 40% of research is openly available.

57%43%

with international co-authors57.3%domestic only42.7%

World: 18% is written across borders.

How has Moberg Pharma (Sweden)'s research output changed?

Output in 2022-2025 was 40% lower than in 2018-2021.

grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Moberg Pharma (Sweden) as a percentage of every work published that year, 0.0000046% in 2023.

Fractional works of Moberg Pharma (Sweden) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Bromma

All research institutions in Bromma

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Moberg Pharma (Sweden). Posts are plain text and can be reported.